Rituximab in CD20 positive multiple myeloma

Leukemia. 2007 Apr;21(4):835-6. doi: 10.1038/sj.leu.2404558. Epub 2007 Feb 1.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD / genetics
  • Antigens, CD20 / genetics*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Gene Expression Regulation, Neoplastic / immunology
  • Humans
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Prospective Studies
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab